FGFR2 and cancer: The detailed characterization of the FGFR2::SHTN1 fusion’s genetic and protein architecture, combined with our findings on Shootin1’s intrinsic oligomerization capabilities, allowed us to propose a comprehensive model for its constitutive activation in cancer (Figure 6A).